Sign in

CIK 0001642380 · Non-accelerated filer<br>Smaller reporting company

Insight Molecular Diagnostics Inc.

Sign in to watch
Ticker
IMDX
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
CA
Entity type
operating
EIN
271041563
Phone
949-409-7600
Business address
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE, TN, 37217
Former names
OncoCyte Corp, Oncocyte Corp
  1. 4 Open-market buy President & CEO bought 40,000 shares at $0.96 ($38,400)
  2. 4 Grant or award Chief Scientific Officer acquired 150,000 shares (grant or award)
  3. 4 Grant or award President & COO acquired 525,000 shares (grant or award)
  4. 4 Grant or award Director acquired 10,000 shares (grant or award)
  5. 4 Open-market buy Director bought 10,000 shares at $0.97 ($9,700)
  6. 4 Grant or award Chief Financial Officer acquired 150,000 shares (grant or award)
  7. 4 Open-market buy Director bought 25,000 shares at $0.93 ($23,250)
  8. 4 Open-market buy Director bought 10,000 shares at $1.00 ($10,000)
  9. 4 Open-market buy Director bought 10,500 shares at $0.95 ($9,975)
  10. 4 Open-market buy Director bought 150,000 shares at an average $0.96 ($144,121)
  11. 3 Insider Initial Statement of Ownership
  12. 4 Option exercise Director acquired 10,000 shares (option exercise)
  13. 4 Option exercise Director acquired 10,000 shares (option exercise)
  14. 4 Option exercise Director acquired 10,000 shares (option exercise)
  15. 4 Option exercise Director acquired 10,000 shares (option exercise)
  16. 4 Option exercise Director acquired 10,000 shares (option exercise)
  17. 4 Option exercise Director acquired 10,000 shares (option exercise)
  18. 4 Open-market sale 10% owner sold 99,386 shares at an average $1.03 ($102,635)
  19. 4/A Open-market buy 10% owner bought 200,000 shares at an average $1.25 ($250,350)
  20. 4 Derivatives Options or other derivatives

Page 5 of 13 · 257 filings